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Abstract Previous studies showed an association of the
common functional polymorphism (C34T, Gln12Stop) in
the adenosine monophosphate deaminase-1 (AMPD1) gene
with survival in heart failure (HF) and/or coronary artery
disease (CAD). The aim of the study was to search for other
mutations in selected regions of the AMPD1 gene in Polish
CAD and HF patients, and to analyze their associations
with obesity and diabetes. Exons 2, 3, 5, and 7 of AMPD1
were scanned for mutations in 97 patients with CAD
without HF (CAD+ HF−), 104 patients with HF (HF+), and
200 newborns from North-Western Poland using denaturing
high-performance liquid chromatography (DHPLC), polymerase
chain reaction–restriction fragment length polymorphism (PCR-
RFLP), and direct sequencing. Frequencies of AMPD1 C34T
mutation, as well as novel A99G, G512A, IVS4-6delT, and
C784T sequence alterations, were similar in the three groups,
but 860T mutated allele was less frequent in the combined
CAD+ HF− and HF+ groups than in the controls (1.7% vs.
4.3%, p=0.040). Heterozygous 34CT genotype was associated
with lower (odds ratio [OR]=0.32, 95% confidence interval
[CI]=0.13–0.81) and 860AT with higher (OR=13.7, 95%CI=
1.6–118) prevalence of diabetes or hyperglycemia in relation to
wild-type homozygotes. Abdominal obesity was more frequent
in 860AT patients than in wild-type homozygotes and 34CT
heterozygotes (86% vs. 40% vs. 29%, p<0.05). Nine genes
containing polymorphisms linked with AMPD1 C34T mutation
were found in the HapMap database. AMPD1 C34T nonsense
mutation is associated with reduced prevalence of diabetes and
obesity in patients with CAD or HF, but A860T substitution
seems to exert opposite metabolic effects and should always be
accounted for in the studies of the AMPD1 genotype.
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Introduction
Previous studies showed an association of the common
C34T polymorphism in the AMPD1 gene with survival in
patients with heart failure (HF) and coronary artery
disease (CAD). Adenosine monophosphate deaminase
(AMPD, EC 3.5.4.6) catalyzes the deamination of
adenosine monophosphate (AMP) to inosine monophosphate
(IMP).TheAMPD1 gene located at 1p13 encodes isoenzyme
which expresses the highest activity in skeletal muscles
(Morisaki et al. 1990). The AMPD2 and AMPD3 genes
encode liver and erythrocyte isoenzyme, respectively. The
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DOI 10.1007/s13353-010-0009-xAMPD1 gene sequence consists of 22,455 base pairs (bp)
including 16 exons (RefSeq NG_008012) (Sabina et al.
1990). 2,341-bp mRNA (RefSeq NM_000036.1) encodes the
747-aa protein (RefSeq NP_000027.1, Swiss-Prot P23109).
The common C34T (Gln12Stop, rs17602729) polymor-
phism in the AMPD1 gene results in a premature stop
codon in exon 2, and, thus, in an inactive enzyme. T34
allele frequency in Europeans amounts to 10–15%
( M o r i s a k ie ta l .1992;N o r m a ne ta l .1998). About 2%
of Europeans are 34TT homozygotes (Norman et al.
1998). For many years, the lack of AMPD activity in
muscles was considered as the cause of myopathy (MIM
102770) (Sabina et al. 1980). However, subsequent studies
showed that most subjects with 34TT genotype, in spite of
no detectable activity of AMPD in muscles, did not
present any myopathy symptoms (Gross 1997).
C34T mutation is linked with C143T (rs61752479,
Pro48Leu) substitution in exon 3, which does not affect
enzyme function in vitro (Morisaki et al. 1992), but it is
difficult to estimate its influence in vivo due to the linkage
disequilibrium with C34T. Less frequent AMPD1 mutations
were found in exons 5 (G468T, Gln156His) (Gross et al.
2002; Fischer et al. 2005) and 7 (A860T, Lys287Ile,
rs34526199) (Toyama et al. 2004). Additionally, mutations
in exons 3 (A44G, Asp15Gly) (Gross et al. 2002),
8 (G930T, Met310Ile) (Toyama et al. 2004), 9 (C1162T,
Arg388Trp), and 10 (G1274A, Arg425His) (Morisaki et al.
2000), as well as splice site deletion in intron 2 IVS2-(4-7)
delCTTT (Isackson et al. 2005), resulting in an enzyme
with very low or no activity, were described in single
patients or families.
Some reports suggested that T34 allele was associated
with improved outcome in patients with HF (Loh et al.
1999; Gastmann et al. 2004; Yazaki et al. 2004) and
improved cardiovascular survival in patients with CAD
(Anderson et al. 2000), while other reports did not confirm
such associations (Andreassi et al. 2005; Kolek et al. 2005;
de Groote et al. 2006). The results of the Collins et al. study
(2006) suggested that the T34 allele was associated with
poorer outcome in patients with a history of myocardial
infarction. No previous reports analyzed the associations of
other polymorphisms in the AMPD1 gene with the
phenotype of cardiovascular diseases.
Metabolic syndrome including obesity and diabetes is a
major risk factor for CAD. The association of AMPD1
C34T mutation with components of the metabolic
syndrome in Polish patients with cardiovascular diseases
was previously analyzed (Safranow et al. 2009). The aim
of the current study was to search for other mutations in
selected regions of the AMPD1 gene in Polish patients
with CAD or HF, as well as in newborns treated as the
genetic control group, and to analyze their associations with
obesity and diabetes. We also investigated the linkage
disequilibrium between the AMPD1 mutations and sequence
alterations of neighboring genes.
Materials and methods
The study groups comprised of patients treated at the
Department of Cardiology, Pomeranian Medical University
in Szczecin, in the years 2004–2006. The patients were all
of Polish descent and most of them were from Szczecin and
its nearby neighborhood (North-Western Poland). The
patients included in this study were clinically stable, with
optimal pharmacological treatment and no acute coronary
syndromes,HFexacerbations,orrevascularizationprocedures
within the last month. This study was approved by the
institutional Ethics Committee. Informed consent was
obtained from each patient.
CAD diagnosis was based on coronary angiography. The
criteria for HF diagnosis included the presence of clinical
symptoms, HF features in echocardiography, and elevated
plasma B-type natriuretic peptide (BNP) concentration.
Patients with hemodynamically significant congenital or
acquired valve diseases were excluded.
The CAD+ HF− group comprised 97 patients aged 58.2±
8.6 years (77% men) with CAD (duration of symptoms 6.2±
5.9 years, 67% with past myocardial infarct) but without HF.
The HF+ group comprised 104 patients aged 58.9±9.6 years
(79% men) with HF (duration of symptoms 4.7±5.0 years,
New York Heart Association [NYHA] class 2.1±0.8). In 70
patients (67%), the etiology of HF was ischemic, in 23 (22%)
it was non-ischemic, and in 11 patients (11%) it was complex.
The control group consisted of 200 consecutive
newborns (96 males) of Polish origin born at the Department
of Neonatology, Pomeranian Medical University in Szczecin,
in the years 2004–2005. DNA was isolated from their
umbilical cord blood.
Genotyping
Genomic DNA was extracted from 0.15 mL of K3EDTA-
anticoagulated blood with a QIAamp DNA Mini Kit
(QIAGEN). The previously described polymerase chain
reaction–restriction fragment length polymorphism (PCR-
RFLP) method with Tai I restriction enzyme was used to
detect C34T substitution in exon 2 of the AMPD1 gene
(Safranow et al. 2009).
For denaturing high-performance liquid chromatography
(DHPLC) analysis and for direct sequencing of exons 2, 3,
5, and 7, DNA was amplified by PCR using exon-flanking
primers (Table 1). The reaction was carried out in a total
volume of 25 mL containing: 40 ng of template DNA, 7.5
pmol of each primer (HPSF, MWG-Biotech AG), PCR
buffer (10 mM Tris-HCl, 50 mM KCl, pH=8.9), 2 mM
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(POLGEN). To minimize artifacts associated with replica-
tion errors of the exon 5 sequence, which contains a tract of
12 T nucleotides, high-fidelity Optimase (Transgenomic)
polymerase with included buffer and 2.5 mM MgSO4 was
used for this amplicon. The amplification was performed
using the GeneAmp PCR System 9700 (Applied Biosystems)
with initial denaturation at 94°C for 5 min and then 35 cycles
as follows: denaturation at 94°C (30 s), annealing at 58°C for
the first five cycles and 56°C for the subsequent 30 cycles
(40s),andextensionat72°C(45s).Thefinal72°Cincubation
was extended by 5 min. The quality of PCR products was
controlled by electrophoresis on 2% agarose gel stained with
ethidium bromide, photographed in UV light.
DHPLC analyses were performed with the Hewlett-
Packard 1050/1100 system and a Helix DNA column
(CP28353, Varian) (Kurzawski et al. 2002). PCR products
were denatured (95°C, 5 min) and reannealed by slowly
decreasing the temperature (1°C/min) to allow the forma-
tion of heteroduplexes. Then, a 5–10-mLs a m p l ew a s
injected into the column. The optimal temperature for the
analysis of heteroduplexes was initially calculated with the
DHPLC Melt Program (http://insertion.stanford.edu/melt.
html) (Jones et al. 1999) and subsequently adjusted based
on experiments to achieve optimal separation of the homo-
and heteroduplexes for each amplicon (Table 1).
Samples with DHPLC profiles different from wild-type
homozygote were directly sequenced in the forward and
reverse directions with the ABI PRISM Dye Terminator
Cycle Sequencing Ready Reaction (Applied Biosystems)
according to the manufacturer’s protocols. Sequences were
read with the DNA 377 or 3130 analyzer (Applied
Biosystems).
Bioinformatics
Protein and DNA sequences of the AMPD1 gene in human
and 27 other vertebrates were compared using the University
of California Santa Cruz (UCSC) Genome Browser (http://
genome.ucsc.edu/). We analyzed the genomes of Homo
sapiens (NCBI sequence version 36.1), 19 mammals (Pan
troglodytes, Macaca mulatta, Otolemur garnettii, Tupaia
belangeri, Mus musculus, Rattus norvegicus, Cavia porcel-
lus, Oryctolagus cuniculus, Sorex araneus, Erinaceus
europaeus, Canis familiaris, Felis catus, Bos taurus, Equus
caballus, Dasypus novemcinctus, Loxodonta africana,
Echinops telfairi, Monodelphis domestica, Ornithorhynchus
anatinus), lizard (Anolis carolinensis), chicken (Gallus
gallus), frog (Xenopus tropicalis), and five fish species
(Danio rerio, Tetraodon nigroviridis, Takifugu rubripes,
Gasterosteus aculeatus, Oryzias latipes). Analyses of some
loci were limited to a lower number of species when the
sequence data were not available.
The BLASTP 2.2.18 program (Altschul et al. 1997)w a s
used to compare human amino acid sequences with inverte-
brates and other species. Exonic splicing enhancer (ESE) and
exonic splicing silencer (ESS) sequences were searched with
the ESEfinder (Cartegni et al. 2003)a n dF A S - E S S( W a n ge t
al. 2004) programs. Linkage disequilibrium between AMPD1
C34T mutation and polymorphisms of other genes located in
its vicinity were analyzed using the HapMap database
(version 23a) (International HapMap Consortium 2007).
Statistical analysis
Genotype and allele frequencies as well as other qualitative
variables were analyzed with Fisher’s exact test (two-sided)
implemented in the SISA Tables program (Quantitative
Skills) (Agresti 1992). The exact test was also applied to
assess the conformity of the genotype distribution to the
Hardy–Weinberg law (Guo and Thompson 1992). When
tables were too large for exact tests, the
2 test was used.
Confidence intervals for allele frequencies were calculated
with the exact test (Clopper and Pearson 1934). Quantitative
variables were compared between genotype groups with the
Mann–Whitney test.
Haplotype and linkage disequilibrium analyses were
performed with the HaploView 4.0 program (Barrett et al.
2005). Lewontin’sDvalue, its 95% confidence interval,
r
2, and LOD score were calculated for each loci pair.
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Table 1 Primer sequences and denaturing high-performance liquid chromatography (DHPLC) temperature for the analysis of the AMPD1 gene
fragments
AMPD1 amplicon Sense and antisense primer Product length (bp) Optimal temperature of DHPLC separation (°C)
Exon 2 5′-ATTCCCAAGCTTTCTGATGG-3′ 210 57
5′-CTCTGACAAATGGCAGCAAA-3′
Exon 3 5′-AGGGGCTTGAACACTAATATG-3′ 274 61
5′-GGCAGATACCCCTCCTTAG-3′
Exon 5 5′-TTTCGTGGGATTGACTCTGA-3′ 341 59.5
5′-GGGGCCAAAGATGATTATGA-3′
Exon 7 5′-GAATGCCTGAAACTTTTTGGA-3′ 222 61
5′-GAATTGTTTTTGCCCAGGAA-3′
χ
′Results
Genotype data
No deviation from the Hardy–Weinberg equilibrium (p>
0.05) was observed for the AMPD1 genotypes in the two
study groups and in the controls (Table 2). Mutated 860T
allele was less frequent in both study groups than in the
controls, and the difference between the combined CAD+
HF− and HF+ group (n=201) and newborns reached
statistical significance (1.7 vs. 4.3%, p=0.040). No other
significant differences in the AMPD1 genotype and allele
frequencies were found between the three groups.
Due to linkage disequilibrium, the T allele in locus 34
was almost always accompanied by the T allele in locus
143, except for two subjects with the 34CC-143CT
genotype. There were two subjects with the 34CT-
143CT genotype and concomitant G512A substitution
and one with a 34CT-143CT-860AT combination. All other
512A and 860T alleles were detected in 34CC-143CC
homozygotes.
Three new variants were found and confirmed by direct
sequencing. Synonymous substitution A99G (Gly33Gly) in
exon 3 was detected in two newborns (99G allele
frequency: 0.25%, 95%CI: 0.03–0.9%). It was added to
the dbSNP recently as rs61752480. Deletion IVS4-6delT in
intron 4, which results in truncation of the T-tract located
just before the start of exon 5 from 12T to 11T, was found
in one allele of a newborn (IVS4-6delT allele frequency:
0.12%, 95%CI: 0.003–0.7%). Substitution C784T
(Arg262Trp) in exon 7 was detected in one allele of a
CAD+ HF− patient (784T allele frequency: 0.12%, 95%CI:
0.003–0.7%).
The haplotypes consisting of seven polymorphic sites,
estimated using expectation–maximization algorithm, are
shown in Table 3. No significant differences in the AMPD1
haplotype distribution were found between groups. The
frequency of the major haplotype was 79.1% in the
combined groups (n=401). The haplotype carrying the
34T allele had a frequency of 16.2% and the remaining
haplotypes were at 4.7%.
Obesity and diabetes
Table 4 compares parameters associated with the metabolic
syndrome (obesity, history of diabetes, fasting glycemia)
Table 2 Frequency distribution of AMPD1 sequence alterations in patients with coronary artery disease without heart failure (CAD+ HF−, n=97),
patients with heart failure (HF+, n=104), newborn controls (n=200), and all combined groups (n=401)
Polymorphism/group Genotype frequency (%) p-value
a Minor allele frequency (95%CI)
b (%) p-value
c HWE p-value
d
C34T CC CT TT T
CAD+ HF− 70.1 23.7 6.2 0.29 18.0 (12.9–24.2) 0.70 0.076
HF+ 71.1 26.0 2.9 15.9 (11.2–21.6) 0.72
Newborns 70.5 28.0 1.5 15.5 (12.1–19.4) 0.43
All 70.6 26.4 3.0 16.2 (13.7–19.0) 0.58
C143T CC CT TT T
CAD+ HF− 69.1 24.7 6.2 0.30 18.6 (13.4–24.8) 0.67 0.088
HF+ 71.1 26.0 2.9 15.9 (11.2–21.6) 0.72
Newborns 70.0 28.5 1.5 15.7 (12.3–19.7) 0.43
All 70.1 26.9 3.0 16.5 (14.0–19.2) 0.72
G512A GG GA AA A
CAD+ HF− 95.9 4.1 0 0.16 2.1 (0.6–5.2) 0.16 1.0
HF+ 98.1 1.9 0 1.0 (0.1–3.4) 1.0
Newborns 99.0 1.0 0 0.5 (0.1–1.8) 1.0
All 98.0 2.0 0 1.0 (0.4–2.0) 1.0
A860T AA AT TT
CAD+ HF− 95.9 4.1 0 0.12 2.1 (0.6–5.2) 0.13 1.0
HF+ 97.1 2.9 0 1.4 (0.3–4.2) 1.0
Newborn 91.5 8.5 0 4.3 (2.5–6.7) 1.0
All 94.0 6.0 0 3.0 (1.9–4.4) 1.0
aFor all genotype frequencies in the three groups
b95% confidence interval for minor allele frequency
cFor allele frequencies in the three groups
dExact test for deviation of genotype frequencies from the Hardy–Weinberg equilibrium
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loci, 34CT heterozygotes, and 860AT heterozygotes. Due to
the low number of 860T carriers (n=7), the CAD+ HF− and
HF+ groups were combined. Higher body mass index
(BMI), prevalence of diabetes (particularly when combined
with hyperglycemia), and abdominal obesity were observed
in 860AT compared to 34CT heterozygotes. There was also
a high proportion of women among 860AT patients. The
presence of C34T mutation is associated with lower (odds
ratio [OR]=0.32, 95%CI=0.13-0–81) and the presence of
A860T with higher (OR=13.7, 95%CI=1.6–118) prevalence
of diabetes or hyperglycemia in relation to wild-type
homozygotes (34CT<WT<860AT).
Linkage disequilibrium analysis of AMPD1 C34T
and SNPs in neighboring genes
Table 5 presents the linkage disequilibrium analysis of
AMPD1 C34T mutation and 1,728 single-nucleotide
polymorphisms (SNPs) located in known genes at the
distance of up to 1,000,000 base pairs downstream and
upstream from C34T. It is based on HapMap data for the
Table 3 Frequency distribution of haplotypes comprising C34T,
A99G, C143T, IVS4-6delT, G512A, C784T, and A860T AMPD1
gene sequence alterations in patients with coronary artery disease
without heart failure (CAD+ HF−, n=97), patients with heart failure
(HF+, n=104), and newborn controls (n=200).
Haplotype Group
C34T A99G C143T IVS4 -6delT G512A C784T A860T CAD+ HF− HF+ Newborns
C A C T G C A 149 (76.8%) 170 (81.7%) 315 (78.8%)
T A T T G C A 35 (18.0%) 33 (15.9%) 62 (15.5%)
CAC T G C T 4 (2.1%) 3 (1.4%) 17 (4.2%)
CAC T A C A 4 (2.1%) 2 (1.0%) 2 (0.5%)
CAT T G C A 1 (0.5%) 0 (0%) 1 (0.25%)
C G C T G C A 0 (0%) 0 (0%) 2 (0.5%)
CAC T G T A 1 (0.5%) 0 (0%) 0 (0%)
CAC - G C A 0 (0%) 0 (0%) 1 (0.25%)
Alleles different from the wild type are shown in bold
p=0.34, Chi-square test for all haplotype frequencies in the three groups
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Table 4 Comparison of clinical data in a combined group of CAD+ HF− and HF+ patients stratified according to the AMPD1 genotype
AMPD1 genotype WT (n=128) 34CT (n=49) 860AT (n=7) Statistical significance
a
34CT vs.
WT
860AT vs.
WT
860AT vs.
34CT
Age (years) 59.3±8.3 57.8±9.7 59.1±8.7 0.25 0.88 0.66
Female gender 26 (20%) 9 (18%) 4 (57%) 0.84 0.043 0.043
BMI (kg/m
2) 28.2±4.3 27.1±3.3 32.7±7.7 0.21 0.087 0.046
Obesity (BMI ≥30 kg/m
2) 43 (34%) 11 (22%) 4 (57%) 0.20 0.24 0.074
Waist (cm) 97.0±11.3 93.8±11.2 104.3±16.0 0.067 0.18 0.072
Waist ≥102 cm (males) or ≥88 cm (females)
b 51 (40%) 14 (29%) 6 (86%) 0.22 0.041 0.0064
Diabetes type 2 28 (22%) 4 (8%) 4 (57%) 0.048 0.054 0.0055
FPG ≥ 126 mg/dL 32 (25%) 6 (12%) 2 (29%) 0.069 1.0 0.26
Diabetes or FPG ≥ 126 mg/dL 39 (30%) 6 (12%) 6 (86%) 0.012 0.0056 0.00018
FPG – fasting plasma glucose; WT – wild-type for all analyzed loci
aFisher’s exact test for qualitative variables and the Mann–Whitney test for quantitative variables; significant differences are shown in bold
bCriterion of abdominal obesity according to NCEP ATP III (2001)
Data are given as mean ± standard deviation (SD) for quantitative variables or number (percentage) of patients with the indicated feature for
qualitative variablesCEU population containing genotypes of 60 unrelated
subjects of European descent, including 12 (20%) 34CT
heterozygotes and two (3.3%) 34TT homozygotes. No
other AMPD1 sequence alterations described in the
current paper were present in the HapMap database.
A region with strong linkage ranges as far as 400,000 bp
upstream of the AMPD1 gene, up to the TSPAN2 gene.
After the exclusion of pseudogenes, nine genes (TRIM33,
BCAS2, DENND2C, NRAS, CSDE1, SIKE, SYCP1, TSHB,
TSPAN2) contain polymorphisms linked with the AMPD1
C34T mutation. It cannot be excluded that one of these
polymorphisms is directly responsible for the observed
associations with obesity and diabetes, while AMPD1
mutations are just genetic markers without functional
connection to metabolic syndrome.
Discussion
In the current study, we analyzed selected exons of the
AMPD1 gene (where non-synonymous mutations leading to
loss of muscle AMP deaminase activity had been described
Table 5 Linkage analysis of AMPD1 C34T polymorphism (position
115 037 580 on chromosome 1) and other polymorphisms (SNPs)
located in known genes at the distance of up to 1,000,000 base pairs.
LOD score and r
2 values for the most strongly linked polymorphism
in each gene are shown
Gene Chromosome 1 location Number of SNPs Number (%) of SNPs with LOD score >2 Maximal LOD score Maximal r
2
PHTF1 114 041 360 – 114 102 879 17 0 (0%) 0.57 0.019
RSBN1 114 105 977 – 114 156 593 27 0 (0%) 0.89 0.027
PTPN22 114 157 960 – 114 215 857 32 0 (0%) 0.89 0.037
BCL2L15 114 220 959 – 114 231 692 9 0 (0%) 0.47 0.016
AP4B1 114 239 201 – 114 249 215 8 0 (0%) 0.37 0.019
DCLRE1B 114 249 561 – 114 258 217 6 0 (0%) 0.22 0.008
HIPK1 114 273 519 – 114 321 945 24 0 (0%) 0.34 0.017
OLFML3 114 323 553 – 114 326 398 3 0 (0%) 0.42 0.021
LOC100132906 114 345 578 – 114 347 488 1 0 (0%) 0 0
SYT6 114 433 437 – 114 497 995 121 0 (0%) 1.03 0.063
MRP63P1 114 623 147 – 114 623 431 0 –– –
TRIM33 114 736 922 – 114 855 304 41 1 (2%) 2.55 0.149
LOC643586 114 864 161 – 114 881 992 10 2 (20%) 8.65 0.468
BCAS2 114 911 701 – 114 925 788 6 3 (50%) 11.99 0.665
DENND2C 114 928 719 – 115 014 255 42 19 (45%) 11.99 0.665
AMPD1 115 017 245 – 115 039 699 12 7 (58%) 11.99 0.665
NRAS 115 051 108 – 115 061 038 3 2 (67%) 8.93 0.332
CSDE1 115 061 060 – 115 102 147 25 7 (28%) 13.07 0.585
SIKE 115 113 623 – 115 124 831 3 0 (0%) 1.49 0.049
NR1H5P 115 178 857 – 115 199 038 17 5 (29%) 6.72 0.223
SYCP1 115 198 978 – 115 339 514 77 49 (64%) 9.08 0.45
TSHB 115 373 938 – 115 378 464 6 4 (67%) 3.87 0.157
TSPAN2 115 392 155 – 115 433 638 79 43 (54%) 7.33 0.343
NGF 115 630 060 – 115 682 380 100 0 (0%) 1.13 0.056
LOC100132332 115 908 526 – 115 909 576 0 –– –
VANGL1 115 986 097 – 116 042 368 91 0 (0%) 1.18 0.051
PHTF1 – putative homeodomain transcription factor 1; RSBN1 – round spermatid basic protein 1; PTPN22 – protein tyrosine phosphatase, non-
receptor type 22 (lymphoid); BCL2L15 – BCL2-like 15; AP4B1 – adaptor-related protein complex 4, beta 1 subunit; DCLRE1B – DNA cross-link
repair 1B (PSO2 homolog); HIPK1 – homeodomain interacting protein kinase 1; OLFML3 – olfactomedin-like 3; LOC100132906 – similar to
mCG23455, pseudogene; SYT6 – synaptotagmin VI; MRP63P1 – mitochondrial ribosomal protein 63 pseudogene 1; TRIM33 – tripartite motif-
containing 33; LOC643586 – similar to pyruvate kinase, muscle, pseudogene; BCAS2 – breast carcinoma amplified sequence 2; DENND2C –
DENN/MADD domain containing 2C; AMPD1 – adenosine monophosphate deaminase 1; NRAS – neuroblastoma RAS viral (v-ras) oncogene
homolog; CSDE1 – cold shock domain containing E1; SIKE – suppressor of IKK epsilon; NR1H5P – nuclear receptor subfamily 1, group H,
member 5 pseudogene; SYCP1 – synaptonemal complex protein 1; TSHB – thyroid stimulating hormone, beta; TSPAN2 – tetraspanin 2; NGF –
nerve growth factor (beta polypeptide); LOC100132332 – similar to CCR4-NOT transcription complex, subunit 7, pseudogene; VANGL1 – vang-
like 1 (van gogh, Drosophila)
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newborn controls. We chose exon 2 with the well-known
C34T (Gln12Stop) mutation, exon 3 with equally frequent
C143T (Pro48Leu) substitution, exon 5 with G468T
(Gln156His)mutationfoundinthe Germanpopulation(Gross
et al. 2002), and exon 7 with A860T (Lys287Ile) (Toyama et
al. 2004) described in Europeans. The presence of the same
genotype at loci 34 (RFLP method) and 143 (DHPLC) was
an additional proof of correct genotyping: when the results
were discordant, direct sequencing was performed to confirm
the rare combination of genotypes at both loci.
Our results have shown that, in the Polish population,
similarly to other Europeans, the most frequent alterations of
the AMPD1 coding sequence are C34T and C143T, which are
strongly linked with each other. The most numerous group of
Europeans genotyped for the AMPD1 C34T mutation so far is
a cohort of 2,707 healthy British subjects (Webb et al. 2006)
with the frequency of 34T allele equal to 13%, which is at the
lower limit of confidence intervals for our groups (Table 2).
The 34T frequency in a group of 721 healthy subjects from
south-western Germany was 14.5% (Frank et al. 2008), while
in 175 healthy Swedes, it was 13.7% (Norman et al. 1998). It
seems that the 34T allele frequency is similar in various
European populations, including patients and newborns
examined in the current study.
According to previous reports, A860T mutation is
present in 3% alleles of healthy subjects of European
descent (Toyama et al. 2004). The 860T allele frequency
was 2.6% in healthy Americans of European origin
(Isackson et al. 2005) and 2.8% in the healthy German
population (Hanisch et al. 2008). These values are in
agreement with results of the current study (Table 2). Four
other detected sequence alterations (A99G in exon 3, IVS4-
6delT in intron 4, G512A in exon 5, C784T in exon 7) have
not been described previously.
We have not found any case of G468T mutation. This variant
is probably very rare and limited to Germany, since it has not
been detected in 230 subjects (healthy or with myopathy) from
various populations (Toyama et al. 2004) and in 704 healthy
Swedes (Fischer et al. 2007). Similarly, we have not found
del404T mutation in exon 5, which was detected in two of 879
Swedes (Norman et al. 1998; Fischer et al. 2007).
The genotype combination 34TT+143CT was detected in
0.5% of subjects, which is similar to the 0.7% frequency
found inAmericans of European origin (Isackson et al. 2005).
Other previously described rare combinations (34CT+143CC
and 34CT+143TT) (Fishbein et al. 1997) were not found in
our population.
Functional impact of detected AMPD1 sequence alterations
Since our study did not involve the assessment of muscle
AMP deaminase activity, we present the analysis of the
possible impact of the detected alterations on enzyme
function based on the previous reports and comparative
genomics. The C34T mutation in exon 2 (Gln12Stop)
definitely leads to the termination of translation and results
in the lack of immunoreactive protein (Morisaki et al. 1992)
and enzyme activity (about 1% of normal) in homozygotes
(Norman et al. 1998). Alternative splicing excluding exon 2
may partly explain the residual AMPD activity and
hypothetically protect from the metabolic consequences of
the defect (Morisaki et al. 1993), but this theory needs to be
proven.
The C143T transition (Pro48Leu) inmost cases accompanies
C34T and has no functional meaning, since translation
terminates at codon 12. However, it could be introduced into
the protein if exon 2 was excluded due to alternative splicing. A
study analyzing the expression of cDNAwith 143Tand 34C in
Escherichia coli did not show altered enzyme activity
( M o r i s a k ie ta l .1992), but its stability and affinity were not
analyzed, and the influence on human muscle AMPD activity
is unknown. Proline is exceptionally conservative and present
in all analyzed vertebrates at the position corresponding to
Pro48 in human AMPD1, together with adjacent amino acids,
forming the sequence Cys-Pro-Ile. This sequence is also
present in the human AMPD3 protein and all of its orthologs
in vertebrates, while in humanA M P D 2 ,t h es e q u e n c ei sS e r -
Pro-Ile. Proline is conservative also in AMPD proteins of non-
vertebrates (Tyr-Pro-Ile sequence in Caenorhabditis elegans),
a n de v e ni np l a n t s( Arabidopsis thaliana)( H a ne ta l .2006).
The adjacent AMPD1 region encompassing AA 51-60 is a
putative zinc-binding site (Martini et al. 2007) and has an -
helix structure (Mangani et al. 2007). Proline-induced break of
the -helix may be important for proper spatial conformation
of the Zn
2+-binding domain. The remarkable evolutionary
conservativeness of Pro48 needs further investigation, which
could elucidate the effects of C143T substitution in the case of
alternative splicing excluding exon 2.
A860T transversion (Lys287Ile) affects the AMPD1
region responsible for myosin binding. Lysine is totally
conservative in the corresponding position of AMPD1,
AMPD2, and AMPD3 proteins in vertebrates and in most
non-vertebrates and plants. In some protozoa, lysine is
substituted by arginine, a basic amino acid with similar
properties. The recombined mutated protein has decreased
both the activity and affinity for AMP by half in relation to
wild-type enzyme (Toyama et al. 2004). Two reported cases
confirm impaired function of the mutated enzyme in vivo.
The muscle AMPD activity in a subject with myopathy
symptoms who turned out to be a compound heterozygote
with IVS2-(4-7)delCTTTand A860T mutations was 20–25%
of normal (Isackson et al. 2005). Another compound
heterozygote with C34T and A860T mutations had the
activity equal to about 40% of common 34CT heterozygotes
(Hanisch et al. 2008). It seems that the activity of enzyme
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αencoded by 860T allele is 40–50% in relation to the enzyme
encoded by wild-type allele.
G512A transition (Gly171Asp) is the most frequent
AMPD1 alteration not described previously. Gly171 is fully
conservative in all of analyzed AMPD1 proteins in
mammals, chicken, frog, and fish, but it is substituted by
asparagine in lizard. Mammal AMPD2 contains alanine and
AMPD3 may contain alanine, glycine, or threonine.
AMPDs in non-vertebrates contain such different amino
acids as leucine, proline, and glutamate. These data suggest
relatively low conservation and, possibly, the lack of
functional impact of Gly171Asp alteration.
C784T (Arg262Trp) changes arginine residue, which is
veryconservative inAMPD1, AMPD2, and AMPD3 proteins
of all 26 analyzed vertebrates, as well as in AMPD of insects,
nematodes, and most fungi and plants (Arabidopsis thaliana).
In some fungi and protozoa, arginine is substituted by similar
basic lysine or histidine. Only a few protozoa contain other
amino acids (glutamine, tyrosine, aspartate, glutamate). In
FAC1 protein with AMPD activity in A. thaliana,t h e
corresponding Arg (position 350 in the Swiss-Prot O80452
sequence) is located in an -helix structure in the middle of
the His-Arg-Arg sequence, which forms a positively charged
flat surface (Han et al. 2006). These facts suggest the high
probability of functional impact of the C784T substitution.
The intron 4 region with IVS4-6delT alteration
(cttttttttttttggcagGTT) contains a typical splice acceptor
sequence: pyrimidine-rich tract and “ag” at the intron–exon
boundary. The deletion shortens the tract from 12 to 11
thymines. The chimpanzee AMPD1 intron 4–exon 5
boundary is identical to the human sequence, but for the
presence of 11T instead of 12T, just like in the human
IVS4-6delT variant. In other primates, the pyrimidine-rich
tract may be as short as 7 bp. These facts are evidence
against the functional role of the deletion.
Synonymous A99G (Gly33Gly) transition in exon 3
deletes one of five ESE motifs specific for the SF2/ASF
protein (AGGAGGT) with relatively low score (2.43) and
creates the ESS motif (AGGGGG), but it does not affect the
ESE motifs specific for other SR proteins (SC35, SRp40,
SRp55). Adenine is present in eight of ten mammals as
coding nucleotide 99, while guanine is found in two (rabbit
and tenrec). It suggests that the A99G variant lacks
functional significance.
AMPD1 and cardiovascular diseases
Similarly to all earlier studies, we did not find significant
differences in the C34T polymorphism genotype distributions
in the study groups (CAD+ HF− and HF +) and in a random
control group consisting of consecutive newborns from the
same population as the study groups (Table 2). The T34 allele
does not prevent the development of either CAD or HF,
though it seems to protect from the known risk factors of
CAD, such as abdominal obesity and diabetes (Safranow
et al. 2009). We did not find significant differences between
groups for the other detected sequence alterations, but the
860T allele was less frequent in a combined group of
patients than in newborns. It could be interpreted as a
protective effect of the T allele against cardiovascular
diseases, but such a hypothesis should be treated with
caution due to the low number of 860T carriers and
moderate statistical significance.
AMPD1 and diabetes
It was reported that variation in the AMPD1 gene is associated
with insulin clearance and may participate in the syndromes of
insulin resistance (Goodarzi et al. 2005). In the previous paper
(Safranow et al. 2009), we demonstrated that the carriage of
T34 mutated allele in CAD patients without HF is associated
with a lower prevalence of two features of metabolic
syndrome, diabetes and obesity, while in patients with HF, it
is associated with lower fasting glucose. Hypothetically, the
activity of AMPD can influence the activity of AMP-activated
protein kinase (AMPK), which controls cellular energy balance
(e.g., by stimulating cellular glucose uptake), affecting the
development of type 2 diabetes in many ways (Gerbitz et al.
1996). In this study, we compared the influence of C34T and
A860T mutations on obesity and diabetes in a combined group
of patients with and without HF. Surprisingly, their effect
proved opposite: 34CT heterozygotes had a significantly lower
frequency of diabetes than wild-type homozygotes, but in
860AT heterozygotes, the prevalence of diabetes and obesity
was higher than in WT and 34CT patients. These differences
were particularly significant when the presence of diabetes or
fasting plasma glucose 126 mg/dL was analyzed (12% vs.
30% vs. 86% prevalence for 34CT, WT, and 860AT,
respectively). The difference in metabolic effects of the two
mutations might be explained by the different ways of enzyme
protein modification: termination of translation by C34T and
r e d u c t i o no ft h ea c t i v i t yb y4 0 –50% in the case of A860T.
Alternatively, the explanation might be the linkage disequilib-
rium of AMPD1 mutations with functional variants in
neighboring genes.
Linkage analysis of AMPD1 C34T polymorphism
Since the AMPD1 gene is expressed at a high level only in
skeletal muscles, the mechanisms of genotype–phenotype
association between its mutations and clinical features of
patients with cardiovascular diseases remain unclear.
Therefore, a possibility of linkage with unknown sequence
alteration within another gene should be taken into account.
The nine genes containing polymorphisms linked with
AMPD1 C34T mutation (Table 5) play various roles, and in
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≥most cases, their function is poorly understood. TRIM33
encodes transcription corepressor. BCAS2 is expressed in
breast tumors, interacting with estrogen receptors. DENND2C
encodes protein with the DENN domain and unknown
function. Other proteins containing the DENN domain
participate in mitogen-activated protein kinases (MAPK)
pathways. Membrane protein encoded by NRAS oncogene
plays a part in MAPK pathways and in signaling through
insulin receptor. Unr protein encoded by CSDE1 gene is an
RNA chaperon, SIKE participates in the inhibition of
interferon secretion during viral infection, and SYCP1 codes
for synaptonemal transverse filament protein. TSPAN2 enc-
odes a membrane protein classified as one of the tetraspanins,
which participate in the transduction of signals controlling
cell development, activation, growth, and movement. TSHB
encoding the beta subunit of thyrotropic hormone (TSH) is
particularly interesting, since its mutations lead to congenital
secondary hypothyroidism (Karges et al. 2004), while both
hypo- and hyperthyroidism are recognized risk factors for
cardiovascular diseases. We have not found any reports
analyzing the association between polymorphisms of the
above-mentioned genes and cardiovascular diseases.
Conclusions
T h em o s tf r e q u e n tm u t a t i o no ft h eAMPD1 gene in the Polish
population is the C34T substitution, associated with reduced
prevalence of diabetes and obesity in patients with coronary
artery disease (CAD) or heart failure (HF). The A860T
mutation seems to exert metabolic effects differing from C34T
and should always be accounted for in studies of the AMPD1
genotype. The potential association of this mutation with
reduced risk of cardiovascular disease, as well as with
increased prevalence of obesity and diabetes, merits further
study in a larger population of patients. Due to the strong
linkage of AMPD1 mutations with sequence alterations in the
TRIM33, BCAS2, DENND2C, NRAS, CSDE1, SIKE, SYCP1,
TSHB,a n dTSPAN2 genes, it seems prudent to analyze the
effect of these alterations on the associations between clinical
and metabolic parameters and the AMPD1 genotype.
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